NIH senior scientists allege that Eli Lilly

provided financial support for the development of sepsis guidelines in order to market their product, Xigris. From the Boston Globe article:

"'Dr. Peter Q. Eichacker , a senior investigator in NIH's critical care medicine department and primary author of the paper, said patients and physicians deserve guidelines that are free of industry bias and based on 'the best research and clinical experience available.'

Instead, Eichacker and his co authors wrote, pharmaceutical companies see medical guidelines as 'a potentially powerful vehicle for promoting their products.'

Lilly, in a prepared statement, said it was 'proper' to provide funding for the Surviving Sepsis Campaign. `'We do not believe that Lilly had any role in the development of guideline content, beyond funding the initiative,' the company said. 'The campaign worked independently and autonomously, and our funding for these grants was openly disclosed.'"

Apparently this drug has been hotly debated ever since the FDA approved it in 2001 "based largely on a single late-stage study showing it extended survival by 28 days."